The Impact of Glucagon-Like Peptide-1 Agonists on Hip and Knee Arthroplasty and Perioperative Considerations

被引:5
|
作者
Jacofsky, David J. [1 ]
Springer, Bryan D. [2 ,3 ]
Mont, Michael A. [4 ]
Ushakumari, Deepu S. [5 ]
Sladen, Robert N. [6 ]
机构
[1] CORE Inst, Phoenix, AZ 85023 USA
[2] OrthoCarolina Hip & Knee Ctr, Charlotte, NC USA
[3] Atrium Musculoskeletal Inst, Charlotte, NC USA
[4] Rubin Inst Adv Orthoped, Baltimore, MD USA
[5] Scope Anesthesia North Carolina, Charlotte, NC USA
[6] Columbia Univ, Med Ctr, Crit Care Anesthesiol, Irving, NY USA
关键词
glucagon-like peptide-1 agonists; total hip and knee; perioperative management; diabetes; obesity; MORBIDLY OBESE;
D O I
10.1016/j.arth.2023.12.002
中图分类号
R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学(修复外科学)];
学科分类号
摘要
Glucagon-Like Peptide agonists have traditionally been used for glycemic control in diabetic patients. However, there has been a dramatic rise in their utilization for weight loss management. As such, arthroplasty surgeons will encounter an increasing number of patients on these medications, and therefore it is important to understand the implications of their use in the perioperative period. This review will describe the pharmacological actions of these medications as well as the impact on hip and knee arthroplasty patients, and considerations for perioperative management. Because of the rapid adaption and utilization of these drugs, the science is evolving at a fast pace. More and longer-term studies are needed to truly understand the impact of these medications on total joint arthroplasty utilization and in management of these patients in the perioperative period. (c) 2023 Elsevier Inc. All rights reserved.
引用
收藏
页码:1455 / 1458
页数:4
相关论文
共 50 条
  • [1] The Impact of Contemporary Glucagon-like Peptide-1 Receptor Agonists on the Onset, Severity, and Conversion to Arthroplasty in Hip and Knee Osteoarthritis
    Porto, Joshua R.
    Lavu, Monish S.
    Hecht, Christian J.
    Kaelber, David C.
    Sculco, Peter K.
    Heckmann, Nathanael D.
    Kamath, Atul F.
    ORTHOPAEDIC JOURNAL OF SPORTS MEDICINE, 2025, 13 (01)
  • [2] Glucagon-Like Peptide-1 Agonists
    Stanton, Eloise W.
    Manasyan, Artur
    Banerjee, Rakhi
    Hong, Kurt
    Koesters, Emma
    Daar, David A.
    ANNALS OF PLASTIC SURGERY, 2025, 94 (01) : 121 - 127
  • [3] Perioperative management of patients on glucagon-like peptide-1 receptor agonists
    Mizubuti, Glenio B.
    Ho, Anthony M. -H.
    da Silva, Leopoldo Muniz
    Phelan, Rachel
    CURRENT OPINION IN ANESTHESIOLOGY, 2024, 37 (03) : 323 - 333
  • [4] Glucagon-like peptide-1 and glucagon-like peptide-2
    Baggio, LL
    Drucker, DJ
    BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 18 (04) : 531 - 554
  • [5] Cardiometabolic Effects of Glucagon-Like Peptide-1 Agonists
    Sarraju, Ashish
    Kim, Sun H.
    Knowles, Joshua W.
    CURRENT ATHEROSCLEROSIS REPORTS, 2016, 18 (02) : 1 - 8
  • [6] Cardiometabolic Effects of Glucagon-Like Peptide-1 Agonists
    Ashish Sarraju
    Sun H. Kim
    Joshua W. Knowles
    Current Atherosclerosis Reports, 2016, 18
  • [7] The potential of glucagon-like peptide-1 receptor agonists in heart failure
    Kreiner, Frederik Flindt
    Hovingh, G. Kees Kornelis
    von Scholten, Bernt Johan
    FRONTIERS IN PHYSIOLOGY, 2022, 13
  • [8] Effect of glucagon-like peptide-1 receptor agonists in patients with psoriasis
    Al-Badri, Marwa R.
    Azar, Sami T.
    THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM, 2014, 5 (02) : 34 - 38
  • [9] Investigational glucagon-like peptide-1 agonists for the treatment of obesity
    Tomlinson, Brian
    Hu, Miao
    Zhang, Yuzhen
    Chan, Paul
    Liu, Zhong-Min
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2016, 25 (10) : 1167 - 1179
  • [10] Clinical pharmacology of glucagon-like peptide-1 receptor agonists
    Sfairopoulos, Dimitrios
    Liatis, Stavros
    Tigas, Stelios
    Liberopoulos, Evangelos
    HORMONES-INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM, 2018, 17 (03): : 333 - 350